Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients

Journal of Clinical Oncology

Volumn 17, Issue 4, 1999, Pages 1132-1140

  Esposito, MD ^a   Venturini, Marco ^a   Vannozzi, M O ^a   Tolino, G ^a   Lunardi, G ^a   Garrone, O ^a   Angiolini, C ^a   Viale, M ^a   Bergaglio, M ^a   Del Mastro, L ^a   Rosso, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIRUBICIN; EPIRUBICINOL; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC RATE; PLASMA CLEARANCE; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0032937810     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.4.1132     Document Type: Article

References (39)

1. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antimicrotubule agent. J Natl Cancer Inst 82:1247-1259, 1990
2. Ringel I, Horwitz SB: Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 83:288-291, 1991
3. Huizing MT, Sewberath Misser VH, Pieters RC, et al: Taxanes: A new class of antitumor agents. Cancer Invest 13:381-404, 1995
4. Siedman AD: The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 1:247-256, 1995
5. Ravdin PM, Valero V: Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin Oncol 22:17-21, 1995 (suppl 4)
6. Sledge GW Jr, Robert N, Sparano JA, et al: Paclitaxel (Taxol)/ doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 21:15-18, 1994 (suppl 8)
7. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
8. Gehl J, Boesgaard M, Paaske T, et al: Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann Oncol 7:687-693, 1996
9. Bonadonna G, Gianni L, Santoro A, et al: Drugs ten years later: Epirubicin. Ann Oncol 4:359-369, 1993
10. Luck HJ, Thomsenn C, duBois A, et al: Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Semin Oncol 23:33-36, 1996 (suppl 1)
11. Catimel G, Spielman M, Dieras V, et al: Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: A preliminary report on safety. Semin Oncol 23:24-27, 1996 (suppl 1)
12. Conte PF, Baldini E, Gennari A, et al: Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15:2510-2517, 1997
13. Chan S: Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy. Oncology 11:19-24, 1997 (suppl 8)
14. Bourgeois H, Gruia G, Dieras V, et al: Docetaxel (D) in combination with doxorubicin (Dx) as 1st line CT of metastatic breast cancer (MBC): A phase I dose finding study. Proc Am Soc Clin Oncol 15:148, 1996 (abstr 259)
15. Venturini M, Michelotti A, Papaldo P, et al: First line epirubicin (EPI) and taxotere (TXT) in advanced breast cancer: A phase I study. Proc Am Soc Clin Oncol 17:179a, 1998 (abstr 690)
16. Holmes FA, Madden T, Newman RA, et al: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14:2713-2721, 1996
17. Gianni L, Viganò L, Locatelli A, et al: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15:1906-1915, 1997
18. Gianni L, Viganò L, Locatelli A, et al: Different interference of paclitaxel (PTX) on human pharmacokinetics of doxorubicin (DOX) and epirubicin (EPI). Proc Am Soc Clin Oncol 16:224a, 1997 (abstr 786)
19. Bruno R, Hille D, Riva A, et al: Population pharmacokinetic/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196, 1998
20. Bellott R, Robert J, Dieras V, et al: Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorubicinol. Proc Am Soc Clin Oncol 17:221, 1998 (abstr 853)
21. Maessen PA, Mross KB, Pinedo HM, et al: Improved method for the determination of 4′-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography. J Chromatogr 417:339-346, 1987
22. Yamaoaka K, Nakagana T, Uno T: Application of Akaike information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 2:165-175, 1978
23. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Marcel Dekker, 1982
24. Jakobsen P, Steiness E, Bastholt L, et al: Multiple-dose pharmacokinetics of epirubicin at four different dose levels: Studies in patients with metastatic breast cancer. Cancer Chemother Pharmacol 28:63-68, 1991
25. Mross K, Maessen P, van der Vijgh WJF, et al: Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol 6:517-526, 1988
26. Jacobsen P, Sørensen B, Bastholt L, et al: The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil and tamoxifen in metastatic breast cancer patients. Cancer Chemother Pharmacol 35:45-52, 1994
27. Webster LK, Cosson EJ, Stokes KH, et al: Effect of paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer 73:522-524, 1996
28. Millward LK, Cosson EJ, Stokes KH, et al: Cremophor EL changes the pharmacokinetics of doxorubicin. Proc Am Assoc Cancer Res 36:373, 1995 (abstr 2221)
29. Sparreboom A, van Tellingen O, Nooijen WJ, et al: Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 56:2112-2115, 1996
30. Colombo T, Gonzalez Paz O, Zucchetti M, et al: Paclitaxel induces significant changes in epidoxorubicin distribution in mice. Ann Oncol 7:801-805, 1996
31. D'Incalci M, Colombo T, Zucchetti M, et al: Pharmacokinetic interaction between taxanes and anthracyclines: In vivo study in mice. Proc Am Soc Clin Oncol 17:239a, 1998 (abstr 915)
32. Vanhoefer U, Cao S, Harstrick A, et al: Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein. Ann Oncol 8:1221-1228, 1997
33. Weenen H, Lankelma J, Penders PGM, et al: Pharmacokinetics of 4′-epi-doxorubicin in man. Invest New Drugs 1:59-64, 1983
34. Weenen H, Van Maanen JMS, De Planque MM, et al: Metabolism of 4′-modified analogs of doxorubicin: Unique glucuronidation pathway for 4′-epidoxorubicin. Eur J Cancer Clin Oncol 20:919-926, 1984
35. Bachur NR: Biochemical pharmacology of the anthracycline antibiotics, in Sartorelli AC (ed): Cancer Chemotherapy. Washington, DC, American Chemical Society, 1976, pp 58-70
36. Mross K, Hamm K, Hossfeld DK: Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemother Pharmacol 31:369-375, 1993
37. Mross K, Bohn C, Edler L, et al: Randomized phase II study of single-agent epirubicin +/- verapamil in patients with advanced metastatic breast cancer: An AIO clinical trial. Arbeitsgemeinschaft Internistische Onkologie of the German Cancer Society. Ann Oncol 4:45-50, 1993
38. st line chemotherapy of metastatic breast cancer: Final results. Proc Am Soc Clin Oncol 17:151a, 1998 (abstr 579)
39. Trudeau ME, Crump M, Latreille J, et al: Escalating doses of docetaxel and epirubicin as a first line therapy for metastatic breast cancer: A phase I study of the National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol 17:178a, 1998 (abstr 687)